Imepitoin (INNTooltip International Nonproprietary Name), sold under the brand name Pexion, is an anticonvulsant which is used in veterinary medicine in Europe to treat epilepsy in dogs.[1][2][3][4] It was recently approved in the United States.[2][3][4] The drug also has anxiolytic effects.[1][2] It was originally developed to treat epilepsy in humans, but clinical trials were terminated upon findings of unfavorable metabolic differences in smokers and non-smokers.[1][2]
Imepitoin acts as a low-affinity (4,350–5,140 nM; relative to Ki = 6.8 nM for diazepam and Ki = 1.7 nM for clonazepam) partial agonist of the benzodiazepine site of the GABAA receptor (up to 12–21% of the maximal potentiation of diazepam, a full agonist of this site).[1] It is the first partial agonist to be approved for the treatment of epilepsy.[1] The drug also dose-dependently blocks voltage-gated calcium channels.[3] It is not a benzodiazepine; instead, it is an imidazolone, and bears some structural similarities to hydantoin anticonvulsants like ethotoin and phenytoin.[1]
See also
- Separation anxiety in dogs § Benzodiazepine treatment
References
|
|---|
| 5-HT1ARTooltip 5-HT1A receptor agonists | |
|---|
| GABAARTooltip GABAA receptor PAMsTooltip positive allosteric modulators | |
|---|
Gabapentinoids (α2δ VDCC blockers) | |
|---|
| Antidepressants | |
|---|
Sympatholytics (Antiadrenergics) |
- Alpha-1 blockers (e.g., prazosin)
- Alpha-2 agonists (e.g., clonidine, dexmedetomidine, guanfacine)
- Beta blockers (e.g., propranolol, atenolol, betaxolol, nadolol, oxprenolol, pindolol)
|
|---|
| Others | |
|---|
|
|
|---|
| Alcohols | |
|---|
| Barbiturates | |
|---|
| Benzodiazepines | |
|---|
| Carbamates | |
|---|
| Flavonoids | |
|---|
| Imidazoles | |
|---|
| Kava constituents |
- 10-Methoxyyangonin
- 11-Methoxyyangonin
- 11-Hydroxyyangonin
- Desmethoxyyangonin
- 11-Methoxy-12-hydroxydehydrokavain
- 7,8-Dihydroyangonin
- Kavain
- 5-Hydroxykavain
- 5,6-Dihydroyangonin
- 7,8-Dihydrokavain
- 5,6,7,8-Tetrahydroyangonin
- 5,6-Dehydromethysticin
- Methysticin
- 7,8-Dihydromethysticin
- Yangonin
|
|---|
| Monoureides | |
|---|
| Neuroactive steroids | |
|---|
| Nonbenzodiazepines |
- Others: Adipiplon
- CGS-8216
- CGS-9896
- CGS-13767
- CGS-20625
- CL-218,872
- CP-615,003
- CTP-354
- ELB-139
- GBLD-345
- JM-1232
- L-838,417
- Lirequinil (Ro41-3696)
- NS-2664
- NS-2710
- NS-11394
- Pipequaline
- ROD-188
- RWJ-51204
- SB-205,384
- SX-3228
- TGSC01AA
- TP-003
- TPA-023
- TP-13
- U-89843A
- U-90042
- Viqualine
- Y-23684
|
|---|
| Phenols | |
|---|
| Piperidinediones | |
|---|
| Pyrazolopyridines | |
|---|
| Quinazolinones | |
|---|
| Volatiles/gases | |
|---|
| Others/unsorted |
- 3-Hydroxybutanal
- α-EMTBL
- AA-29504
- Alogabat
- Avermectins (e.g., ivermectin)
- Bromide compounds (e.g., lithium bromide, potassium bromide, sodium bromide)
- Carbamazepine
- Chloralose
- Chlormezanone
- Clomethiazole
- Darigabat
- DEABL
- Deuterated etifoxine
- Dihydroergolines (e.g., dihydroergocryptine, dihydroergosine, dihydroergotamine, ergoloid (dihydroergotoxine))
- DS2
- Efavirenz
- Etazepine
- Etifoxine
- Fenamates (e.g., flufenamic acid, mefenamic acid, niflumic acid, tolfenamic acid)
- Fluoxetine
- Flupirtine
- Hopantenic acid
- KRM-II-81
- Lanthanum
- Lavender oil
- Lignans (e.g., 4-O-methylhonokiol, honokiol, magnolol, obovatol)
- Loreclezole
- Menthyl isovalerate (validolum)
- Monastrol
- Nicotinic acid
- Nicotinamide
- Org 25,435
- Phenytoin
- Propanidid
- Retigabine (ezogabine)
- Safranal
- Seproxetine
- Stiripentol
- Sulfonylalkanes (e.g., sulfonmethane (sulfonal), tetronal, trional)
- Terpenoids (e.g., borneol)
- Topiramate
- Valerian constituents (e.g., isovaleric acid, isovaleramide, valerenic acid, valerenol)
- Unsorted benzodiazepine site positive modulators: α-Pinene
- MRK-409 (MK-0343)
- TCS-1105
- TCS-1205
|
|---|
See also: Receptor/signaling modulators • GABA receptor modulators • GABA metabolism/transport modulators |
|
|---|
| Calcium | | VDCCsTooltip Voltage-dependent calcium channels | | Blockers |
- R-type-selective: SNX-482
|
|---|
| Activators | |
|---|
|
|---|
|
|---|
| Potassium | | VGKCsTooltip Voltage-gated potassium channels | | Blockers |
- KCNQ (Kv7)-specific: Linopirdine
- XE-991
- Spooky toxin (SsTx)
|
|---|
| Activators | |
|---|
|
|---|
| IRKsTooltip Inwardly rectifying potassium channel | | Blockers | |
|---|
| Activators |
- GIRKTooltip G protein-coupled inwardly rectifying potassium channel-specific: ML-297 (VU0456810)
|
|---|
|
|---|
| KCaTooltip Calcium-activated potassium channel | |
|---|
| K2PsTooltip Tandem pore domain potassium channel | |
|---|
|
|---|
| Sodium | | VGSCsTooltip Voltage-gated sodium channels | | Blockers |
- Analgesics: AZD-3161
- DSP-2230
- Funapide
- GDC-0276
- NKTR-171
- PF-04531083
- PF-05089771
- Ralfinamide
- Raxatrigine
- RG7893 (GDC-0287)
- Suzetrigine
|
|---|
| Activators | |
|---|
|
|---|
| ENaCTooltip Epithelial sodium channel | |
|---|
| ASICsTooltip Acid-sensing ion channel | |
|---|
|
|---|
| Chloride | | CaCCsTooltip Calcium-activated chloride channel | |
|---|
| CFTRTooltip Cystic fibrosis transmembrane conductance regulator | |
|---|
| Unsorted | |
|---|
|
|---|
| Others | | TRPsTooltip Transient receptor potential channels | |
|---|
| LGICsTooltip Ligand gated ion channels | |
|---|
|
|---|
See also: Receptor/signaling modulators • Transient receptor potential channel modulators |